T

Trial Management Associates, LLC | Wilmington, NC

Research site

(Unclaimed)

Location

1442 Military Cutoff Road, Suite 30, Wilmington, North Carolina, United States of America

Site insights

Top conditions

Top treatments

GED-0301

Relamorelin

Vonoprazan

Iron

PF-00489791

Obeticholic Acid

Daclatasvir

Ferric Carboxymaltose

TVB-2640

Diltiazem Hydrochloride

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 52 total trials

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling

Seasonal Influenza

Biological: Fluarix®

Biological: Influsplit®

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19 (NextCOVE)

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting

COVID-19

Biological: mRNA-1283.222

Biological: mRNA-1273.815

A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immun...

Active, not recruiting

Influenza

SARS-CoV-2

Biological: Investigational Influenza Vaccine 1

Biological: COVID-19 Vaccine 2

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting

Respiratory Syncytial Virus

Drug: Placebo

Drug: mRNA-1345

Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults

This Phase 2/3 study is a multi-portion design to confirm that the chosen formulation and dosing regimen of CoVLP has an acceptable immunogenicity an...

Active, not recruiting

SARS-CoV-2 Infection

Biological: Intramuscular vaccine

Drug: Intramuscular injection